Growth Metrics

Oruka Therapeutics (ORKA) Cash from Financing Activities (2010 - 2026)

Oruka Therapeutics' quarterly Cash from Financing Activities came in at $40.6 million in Q1 2026, up 13524.16% quarter-over-quarter from $298000.0 in Q4 2025.

Oruka Therapeutics has reported Cash from Financing Activities for 14 years, with the latest figure at $40.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $40.6 million; the trailing twelve-month figure through Mar 2026 stood at $210.3 million (changed N/A YoY), and the FY2025 full-year result was $170.3 million, down 62.11% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $40.6 million, up from $298000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $423.7 million in Q3 2024, with the low at -$1.6 million in Q2 2024.
  • Average Cash from Financing Activities over 3 years is $94.3 million, with a median of $27.9 million recorded in 2024.
  • Peak annual rise in Cash from Financing Activities reached 156.65% in 2025, while the deepest fall reached 59.9% in 2025.
  • Tracing ORKA's Cash from Financing Activities over 3 years: stood at -$526000.0 in 2024, then surged by 156.65% to $298000.0 in 2025, then surged by 13524.16% to $40.6 million in 2026.
  • The last three Cash from Financing Activities figures came in at $40.6 million (Q1 2026), $298000.0 (Q4 2025), and $169.9 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 7.00 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 53,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -538.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -802.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 15.71 Mn
10 Oruka Therapeutics 3.04 Bn 2.65 Bn - 40.60 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 40.60 Mn
Mar 31, 2026 40.60 Mn
Dec 31, 2025 298,000.00
Dec 31, 2025 298,000.00
Sep 30, 2025 169.91 Mn
Sep 30, 2025 169.91 Mn
Dec 31, 2024 -526,000.00
Dec 31, 2024 -526,000.00
Sep 30, 2024 423.74 Mn
Sep 30, 2024 423.74 Mn
Jun 30, 2024 -1.59 Mn
Jun 30, 2024 -1.59 Mn
Mar 31, 2024 27.91 Mn
Mar 31, 2024 27.91 Mn
Mar 31, 2021 23.09 Mn
Mar 31, 2021 23.09 Mn
Dec 31, 2020 984,000.00
Dec 31, 2020 984,000.00
Sep 30, 2020 42.06 Mn
Sep 30, 2020 42.06 Mn
Dec 31, 2019 -122,000.00
Dec 31, 2019 -122,000.00
Sep 30, 2019 568,000.00
Sep 30, 2019 568,000.00
Jun 30, 2019 3.15 Mn
Jun 30, 2019 3.15 Mn
Mar 31, 2019 2.96 Mn
Mar 31, 2019 2.96 Mn
Dec 31, 2018 -105,000.00
Dec 31, 2018 -105,000.00
Jun 30, 2018 -207,000.00
Jun 30, 2018 -207,000.00
Mar 31, 2018 3.42 Mn
Mar 31, 2018 3.42 Mn
Dec 31, 2017 7,000.00
Dec 31, 2017 7,000.00
Sep 30, 2017 3.95 Mn
Sep 30, 2017 3.95 Mn
Jun 30, 2017 1.79 Mn
Jun 30, 2017 1.79 Mn
Mar 31, 2017 105,000.00
Mar 31, 2017 105,000.00
Dec 31, 2015 -58,000.00
Dec 31, 2015 -58,000.00
Sep 30, 2015 -200,000.00
Sep 30, 2015 -200,000.00
Jun 30, 2015 34.31 Mn
Jun 30, 2015 34.31 Mn
Mar 31, 2015 -55,000.00
Mar 31, 2015 -55,000.00
Dec 31, 2014 -2,000.00
Dec 31, 2014 -2,000.00
Sep 30, 2014 -51,000.00
Sep 30, 2014 -51,000.00
Jun 30, 2014 -57,000.00
Jun 30, 2014 -57,000.00
Mar 31, 2014 8.13 Mn
Mar 31, 2014 8.13 Mn
Sep 30, 2013 -55,000.00
Sep 30, 2013 -55,000.00
Jun 30, 2013 17.82 Mn
Jun 30, 2013 17.82 Mn
Mar 31, 2013 1.39 Mn
Mar 31, 2013 1.39 Mn
Dec 31, 2012 508,000.00
Dec 31, 2012 508,000.00
Sep 30, 2012 674,000.00
Sep 30, 2012 674,000.00
Jun 30, 2012 -67,000.00
Jun 30, 2012 -67,000.00
Mar 31, 2012 -60,000.00
Mar 31, 2012 -60,000.00
Dec 31, 2011 1.43 Mn
Dec 31, 2011 1.43 Mn
Sep 30, 2011 -40,000.00
Sep 30, 2011 -40,000.00
Sep 30, 2010 1,000.00
Sep 30, 2010 1,000.00